Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1010.6
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1010.6 is an investigational quadrivalent mRNA-based vaccine developed by Moderna for the prevention of seasonal influenza. It is an optimized iteration of the lead candidate mRNA-1010, designed to encode the hemagglutinin (HA) glycoproteins of four seasonal influenza strains recommended by the World Health Organization (WHO): influenza A (H1N1 and H3N2) and influenza B (Yamagata and Victoria lineages). The vaccine utilizes Moderna's proprietary lipid nanoparticle (LNP) delivery system to induce both humoral and cellular immune responses against the viral HA protein, which is essential for viral entry into host cells. mRNA-1010.6 was specifically developed to improve immunogenicity against influenza B strains compared to earlier versions of the program. In late-stage clinical trials, it has demonstrated a favorable safety profile and met primary immunogenicity endpoints.
- Other names
- Quadrivalent mRNA influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA-1010.6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1010.6.